ETF Foundry
DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.
investment factor · long-only model fund

Foundry Healthcare InvestPPEInv Factor ETF

ETF Foundry Research (hypothetical) · rebalanced monthly

FINHHYPOTHETICAL MODEL
Since ’99
−12%
Expense Ratio
0.45%
placeholder
Holdings
95
cap-weighted
Inception
Apr 2020
placeholder
Full Sharpe
0.04
Ann. Return (LS)
0.7%
Ann. Volatility
15.1%
Max Drawdown
-55.4%
Test Sharpe ’19–26
0.02
Test FF5 α (ann.)
5.0%
vs Fama-French 5
Test FF5 α t-stat
0.76
not significant
Monthly turnover
15%
of the long leg, per rebalance
Cumulative return (LS)
-12%
over 331 months
This fund holds the long leg only
Long leg Sharpe
0.53
what this fund holds
Long leg ann. return
9.0%
buyable, long-only
Long-short Sharpe
0.04
requires shorting
Bottom bucket ann. return
8.3%
the basket shorted

Every other metric on this page is the long-shortstrategy, which needs a short book. This fund is the long leg alone, so these are the figures for what it actually holds. The bottom-bucket number is that basket’s own return — not short P&L.

Hypothetical growth of $1 — long-short backtest

Gross of the placeholder expense ratio and trading costs · not investor results

331 months

Holdings

Every constituent of the long leg — sort, search or filter by sector

95 of 95 · 100.0% of book
TickerCompanySectorMarket capWeight
1BDX
BECTON DICKINSON & COHealthcare$43.58B
13.28%
2TEVA
TEVA PHARMACEUTICAL INDUSTRIES LTDHealthcare$37.30B
11.36%
3BIIB
BIOGEN INCHealthcare$30.41B
9.26%
4MRNA
MODERNA INCHealthcare$24.53B
7.47%
5INCY
INCYTE CORPHealthcare$23.42B
7.14%
6EXEL
EXELIXIS INCHealthcare$14.06B
4.28%
7ALGN
ALIGN TECHNOLOGY INCHealthcare$12.66B
3.86%
8CRL
CHARLES RIVER LABORATORIES INTERNATIONAL INCHealthcare$10.81B
3.29%
9KYMR
KYMERA THERAPEUTICS INCHealthcare$9.52B
2.90%
10IBRX
IMMUNITYBIO INCHealthcare$8.04B
2.45%
11LNTH
LANTHEUS HOLDINGS INCHealthcare$7.00B
2.13%
12SRRK
SCHOLAR ROCK HOLDING CORPHealthcare$6.33B
1.93%
13LGND
LIGAND PHARMACEUTICALS INCHealthcare$6.08B
1.85%
14ERAS
ERASCA INCHealthcare$5.96B
1.82%
15TFX
TELEFLEX INCHealthcare$5.96B
1.82%
16TXG
10X GENOMICS INCHealthcare$5.55B
1.69%
17CRSP
CRISPR THERAPEUTICS AGHealthcare$4.61B
1.40%
18TNGX
TANGO THERAPEUTICS INCHealthcare$4.13B
1.26%
19RLAY
RELAY THERAPEUTICS INCHealthcare$3.81B
1.16%
20ADPT
ADAPTIVE BIOTECHNOLOGIES CORPHealthcare$3.67B
1.12%
21BKD
BROOKDALE SENIOR LIVING INCHealthcare$3.58B
1.09%
22NHC
NATIONAL HEALTHCARE CORPHealthcare$3.56B
1.09%
23HAE
HAEMONETICS CORPHealthcare$3.54B
1.08%
24ESTA
ESTABLISHMENT LABS HOLDINGS INCHealthcare$2.72B
0.83%
25KOD
KODIAK SCIENCES INCHealthcare$2.67B
0.81%
26QURE
UNIQURE NVHealthcare$2.54B
0.77%
27VCEL
VERICEL CORPHealthcare$2.38B
0.73%
28NKTR
NEKTAR THERAPEUTICSHealthcare$2.31B
0.70%
29AUPH
AURINIA PHARMACEUTICALS INCHealthcare$2.05B
0.63%
30MRVI
MARAVAI LIFESCIENCES HOLDINGS INCHealthcare$1.87B
0.57%
31BFLY
BUTTERFLY NETWORK INCHealthcare$1.73B
0.53%
32NTLA
INTELLIA THERAPEUTICS INCHealthcare$1.59B
0.48%
33INNV
INNOVAGE HOLDING CORPHealthcare$1.56B
0.48%
34MAZE
MAZE THERAPEUTICS INCHealthcare$1.56B
0.47%
35AMN
AMN HEALTHCARE SERVICES INCHealthcare$1.36B
0.41%
36NVAX
NOVAVAX INCHealthcare$1.35B
0.41%
37ABSI
ABSCI CORPHealthcare$1.29B
0.39%
38INBX
INHIBRX BIOSCIENCES INCHealthcare$1.28B
0.39%
39TNDM
TANDEM DIABETES CARE INCHealthcare$1.17B
0.36%
40SDGR
SCHRODINGER INCHealthcare$1.14B
0.35%
41WVE
WAVE LIFE SCIENCES LTDHealthcare$1.12B
0.34%
42PCRX
PACIRA BIOSCIENCES INCHealthcare$1.01B
0.31%
43BVS
BIOVENTUS INCHealthcare$1.01B
0.31%
44VOR
VOR BIOPHARMA INCHealthcare$980M
0.30%
45ANNX
ANNEXON INCHealthcare$950M
0.29%
46TBPH
THERAVANCE BIOPHARMA INCHealthcare$873M
0.27%
47ZVRA
ZEVRA THERAPEUTICS INCHealthcare$755M
0.23%
48AURA
AURA BIOSCIENCES INCHealthcare$723M
0.22%
49OMER
OMEROS CORPHealthcare$701M
0.21%
50TCMD
TACTILE SYSTEMS TECHNOLOGY INCHealthcare$648M
0.20%
51STTK
SHATTUCK LABS INCHealthcare$577M
0.18%
52WEAV
WEAVE COMMUNICATIONS INCHealthcare$575M
0.18%
53FDMT
4D MOLECULAR THERAPEUTICS INCHealthcare$575M
0.18%
54ANGO
ANGIODYNAMICS INCHealthcare$558M
0.17%
55DNA
GINKGO BIOWORKS HOLDINGS INCHealthcare$517M
0.16%
56RGNX
REGENXBIO INCHealthcare$511M
0.16%
57NRC
NRC HEALTHHealthcare$491M
0.15%
58VMD
VIEMED HEALTHCARE INCHealthcare$466M
0.14%
59ENTA
ENANTA PHARMACEUTICALS INCHealthcare$400M
0.12%
60STRO
SUTRO BIOPHARMA INCHealthcare$391M
0.12%
61ZNTL
ZENTALIS PHARMACEUTICALS INCHealthcare$364M
0.11%
62LYEL
LYELL IMMUNOPHARMA INCHealthcare$311M
0.09%
63TKNO
ALPHA TEKNOVA INCHealthcare$291M
0.09%
64TRDA
ENTRADA THERAPEUTICS INCHealthcare$268M
0.08%
65QTTB
Q32 BIO INCHealthcare$255M
0.08%
66SRZN
SURROZEN INCHealthcare$255M
0.08%
67ARTV
ARTIVA BIOTHERAPEUTICS INCHealthcare$241M
0.07%
68KPTI
KARYOPHARM THERAPEUTICS INCHealthcare$216M
0.07%
69AGEN
AGENUS INCHealthcare$209M
0.06%
70IMUX
IMMUNIC INCHealthcare$207M
0.06%
71BDSX
BIODESIX INCHealthcare$204M
0.06%
72FOCL
FOCAL INCHealthcare$204M
0.06%
73DTIL
PRECISION BIOSCIENCES INCHealthcare$203M
0.06%
74AMWL
AMERICAN WELL CORPHealthcare$199M
0.06%
75DERM
JOURNEY MEDICAL CORPHealthcare$197M
0.06%
76PDEX
PRO DEX INCHealthcare$183M
0.06%
77INFU
INFUSYSTEM HOLDINGS INCHealthcare$180M
0.05%
78INGN
INOGEN INCHealthcare$178M
0.05%
79KRRO
KORRO BIO INCHealthcare$177M
0.05%
80ARCT
ARCTURUS THERAPEUTICS HOLDINGS INCHealthcare$172M
0.05%
81RCEL
AVITA MEDICAL INCHealthcare$157M
0.05%
82CUE
CUE BIOPHARMA INCHealthcare$126M
0.04%
83ICCC
IMMUCELL CORPHealthcare$101M
0.03%
84VRCA
VERRICA PHARMACEUTICALS INCHealthcare$96M
0.03%
85CSBR
CHAMPIONS ONCOLOGY INCHealthcare$85M
0.03%
86ACET
ADICET BIO INCHealthcare$76M
0.02%
87ATRA
ATARA BIOTHERAPEUTICS INCHealthcare$76M
0.02%
88CLNN
CLENE INCHealthcare$76M
0.02%
89AGPU
AXE COMPUTE INCHealthcare$72M
0.02%
90LONA
LEONABIO INCHealthcare$68M
0.02%
91IMA
IMAGENEBIO INCHealthcare$61M
0.02%
92INKT
MINK THERAPEUTICS INCHealthcare$53M
0.02%
93XLO
XILIO THERAPEUTICS INCHealthcare$53M
0.02%
94MCRB
SERES THERAPEUTICS INCHealthcare$52M
0.02%
95EXOZ
EXOZYMES INCHealthcare$51M
0.02%

Full long-leg book as of July 2026 · cap-weighted · total market cap $328.25B. Hypothetical model holdings — not a registered fund’s portfolio.

Sector Breakdown

1 sectors
Healthcare
100.0%

Portfolio Style

Size × value map of the long-leg book

95 classified
Value
Blend
Growth
Large
Mid
Small
17%4
33%6
23%7
2%4
5%7
4%7
2%25
1%11
1%7

Share of long-leg capital by market cap × book-to-market, using terciles of the 499-name universe at July 2026. Rows: Large ≥ $3.6B, Small < $964M. Columns: Value ≥ 0.67, Growth < 0.37 B/M. The dot marks the capital-weighted centroid of the book — 89% toward Large, 54% toward Growth. +11% unclassified (17 missing size/value). Hypothetical holdings — descriptive, not realized P&L.

Tilt over time
Size tilt89% → Large
SmallLarge
Value ↔ growth tilt54% → Growth
ValueGrowth

Capital-weighted centroid of the long leg, December 1998July 2026; the right-hand end is the same value as the box’s dot. 95 names now. The faded start covers early months with a much thinner universe. Hypothetical holdings — descriptive, not P&L.

Constraint checks

How this book measures against the concentration and liquidity rules — as implemented here

How this book was built

These are UNCONSTRAINED factor sleeves: the construction pipeline sorts on a signal and cap-weights the top bucket, applying no issuer cap, no industry cap and no liquidity screen beyond the universe filter. A failing test therefore reports a constraint that was never applied during construction — it is not a defect in the strategy and not an error in the data. The same signal can be solved subject to these constraints.

Passed
6
Failed
0
Not tested
1
Independent checks
7

7 independent checks plus 1 arithmetically implied by another check (RIC / IRC 851(b)(3)(A) 50% bucket), which is reported separately so the tally cannot overstate scrutiny.

1 of 7 checks could not be tested. Those are neither passes nor failures — they are gaps in what the data can answer, and they are excluded from the passed count above rather than folded into it.

Reported separately — arithmetically implied

Engineering approximation of the cited rules for a DRAFT / HYPOTHETICAL model portfolio that is not a registered fund. This reports whether the portfolio passes the stated test AS IMPLEMENTED HERE; it is not a compliance opinion and is not a statement that any fund is compliant. Real filings need securities counsel.

No verdict sits within 1.0pp of its limit.

Data version — panel=20260719T025334 rows=2239262 asof=202607 issuers=20260719T014536 rates=20260804T224700

Measured on the 2026-07 formation date across 95 holdings (cap-weighted). A different formation date can produce different verdicts.

Derivatives risk (Rule 18f-4)

Whether this long-only book is subject to the VaR tests at all

This assessment describes the long-only book this fund holds — the top bucket only.

Governing rule
Rule 18f-4(c)(4) limited derivatives user exception

This fund QUALIFIES for the limited-derivatives-user exception, so it is excepted from the VaR tests; the ratio below is informational, not the operative limit.

Limited derivatives user exceptionby construction

Rule 18f-4(c)(4): a fund whose derivatives exposure (gross notional, including the value of assets sold short) is <= 10% of net assets is excepted from the VaR tests and the full derivatives risk management program.

Qualifies
Required
<= 10% of net assets
Exposure
0% of net assets
Margin
+10pp

No confidence interval: this follows from portfolio construction, not from an estimate.

Rule 18f-4(c)(2)(i): fund VaR at 99% over 20 trading days must not exceed 200% of the designated reference portfolio's VaR on the same basis.

Informational — does not govern

This fund is excepted from the VaR tests, so the ratio below is context rather than the operative limit. It is shown because it is still a description of the book’s risk, not because it decides anything.

Measured
1.1 (95% CI 0.7-1.3)
x reference VaR
Limit
2.00x
<= 2.00x reference VaR
Fund VaR
10.8%
99% / 20d
Reference
9.6%
FF5 market (mkt)

historical method · 331 monthly observations · about 3.3 in the 99% tail · paired percentile bootstrap over months

Same test, three estimators
historical
1.12x
within
parametric
1.08x
within
cornish fisher
0.96x
within

The estimators agree, which is mild evidence the number isn’t an artefact of one method.

Engineering approximation of SEC Rule 18f-4 for research display. Not a compliance opinion and not a determination that any fund is compliant. Hypothetical model portfolio, not a registered fund.

The research long-short construction behind this factor does not qualify for this exception — a dollar-neutral book counts its full short notional, which is 100% of net assets against a 10% threshold. This product sidesteps that by holding the long leg alone, which is also why the long-leg Sharpe is reported separately throughout the site.

See the long-short verdict on the factor page →

Since publication

Did the edge survive the paper coming out?

published 2008
Before publication (pre-2008)
0.11
Sharpe · 1.7% p.a.
January 1999December 2008 · 120 mo
Since publication
0.01
Sharpe · 0.1% p.a.
January 2009July 2026 · 211 mo
Change in Sharpe−0.10Sharpe weakened since publication

Split at January of the year after the factor was published. The post-publication stretch IS genuinely out-of-sample relative to the original study -- the predictor was public by then -- so it speaks to whether the effect survived being known. Nothing is fitted here, so this is performance SINCE PUBLICATION, not validation of a model. Note the 'pre' side is our data before publication (our panel starts ~1999), NOT the study's original in-sample period, which usually ran decades earlier; a decay figure compares before-vs-after within our sample and is not a comparison against the published result.

Consistency across eras

Is this record broadly durable, or one regime?

26 windows
Positive windows
46%
12 of 26 3-year windows made money
Worst window
-0.77
Sharpe, January 2013 – December 2015
January 1999July 2026
Median Sharpe
-0.14
Dispersion
0.40
Best window
0.93

3-year rolling windows, stepping 1 year (26 windows). Dispersion is the spread of window Sharpes — higher means the record depends more on which era you look at.

Rules-based factors fit no parameters, so these windows are not out-of-sample tests and do not validate a fitted model. They show whether the factor's record is consistent across eras or driven by one regime.

Returns

Long leg is what this fund holds — long-short is shown for reference

since January 1999
Trailing
PeriodLong legLong-short
1 yearcum.51.1%16.0%
3 yearsp.a.10.8%-4.4%
5 yearsp.a.3.5%2.8%
10 yearsp.a.7.6%-2.1%
Since inceptionp.a.7.8%-0.5%
Calendar years
YearLong legLong-short
20267 mo20.0%19.6%
202522.3%-6.1%
2024-0.7%-17.1%
2023-3.4%-10.7%
2022-11.7%28.6%
20218.0%-4.6%
202017.5%-9.6%
201918.7%-1.4%
20182.9%-9.8%
201719.9%0.5%
2016-5.0%1.7%
201510.0%-7.8%
201416.8%-7.6%
201330.2%-5.4%
201220.2%2.2%
201117.1%19.4%
201013.4%3.1%
200912.6%-1.9%
2008-22.7%-10.9%
20076.3%-1.6%
200610.2%13.6%
200510.5%-8.2%
2004-19.0%-17.8%
200358.1%19.4%
2002-25.3%4.3%
2001-4.7%17.6%
200025.7%-20.7%
19995.7%20.7%

Long leg = the top bucket this fund holds; long-short additionally shorts the bottom bucket and is not achievable in a long-only vehicle. Trailing figures run through July 2026: 1 year is a plain cumulative 12-month return (cum.), 3 years and longer are annualised (p.a.). Years marked with a month count are partial. These match the fact sheet’s tables by construction. Hypothetical backtest, gross of the placeholder expense ratio and trading costs — not investor results.

Fund Facts

Ticker (pseudo)FINH
IssuerETF Foundry Research (hypothetical)
SeriesHypothetical Model Portfolio Series (not a registered trust)
Expense ratio0.45% (placeholder)
Inception2020-04-15 (placeholder)
Listing exchangeNot listed (hypothetical)
CUSIPNot applicable (hypothetical model portfolio)
RebalanceMonthly
Holdings as ofJuly 2026
Total mkt cap (long leg)$328.25B

Methodology

The Foundry Healthcare InvestPPEInv Factor ETF tracks a rules-based model that ranks Healthcare common stocks each month by a InvestPPEInv signal and holds the top quintile with the lowest values. Signals are computed from point-in-time Sharadar fundamentals and total-return prices. The portfolio reconstitutes monthly and is cap-weighted within the long leg.

This is a hypothetical model portfolio for research display only — not a registered fund, not an offer, and not investment advice.

Documents (draft — hypothetical)

Auto-generated from the model’s metrics and current holdings. Every document is labeled DRAFT / hypothetical.

Summary Prospectus

Objective, fees, strategy, and key risks.

View →
Prospectus

Full strategy, model methodology, and risks.

View →
Statement of Additional Information

Policies, construction, and governance.

View →
Fact Sheet

One-page snapshot with top holdings.

View →
Daily Holdings

Full current constituent list.

View →

DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.